People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024 Phase 1 clinical trial to evaluate proprietary aerosol ...

On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for ...

Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

Over 600,000 people worldwide die from mosquito-borne malaria each year, with the majority of these deaths happening among ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the ...

Epilepsy is a chronic brain condition where nerve cells in the brain send incorrect signals causing seizures Heres how it ...

Atai Life Sciences N.V. ( (ATAI) ) has released its Q3 earnings. Here is a breakdown of the information Atai Life Sciences N.V. presented to ...

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization ...